NRXP

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NRXP) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (C). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
B+
Factor Score 3.8 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.5
EV / EBITDA -3.7
Rev Growth YoY N/A
Gross Margin 46.6%
Price Return 3M -30.3%
Price Return 12M -8.4%
Catalyst Signal 0.00
Market Cap $98.7M
TTM Revenue $3.4M
Price / Sales 29.1
ROE N/A

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.8) B+ (3.8) C (2.3) C (2.2) C+ (2.6) C+ (2.8)
2026-11-06 C+ (2.8) B+ (3.8) C (2.3) C (2.2) C+ (2.7) C+ (2.8)
2026-10-30 C+ (2.8) B+ (3.7) C (2.3) C (2.5) C+ (2.7) C+ (2.8)
2026-10-23 C+ (2.8) B+ (3.7) C (2.3) C (2.2) C+ (2.6) C+ (2.7)
2026-10-16 C+ (2.8) B+ (3.7) C (2.3) C+ (2.5) C+ (2.6) C+ (2.8)
Page 1 of 4